Mutual of America Capital Management LLC Has $7.45 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Mutual of America Capital Management LLC trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 13.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 278,436 shares of the specialty pharmaceutical company’s stock after selling 42,484 shares during the period. Mutual of America Capital Management LLC owned approximately 0.51% of Supernus Pharmaceuticals worth $7,448,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of SUPN. Congress Wealth Management LLC DE increased its holdings in shares of Supernus Pharmaceuticals by 37.8% in the 1st quarter. Congress Wealth Management LLC DE now owns 177,801 shares of the specialty pharmaceutical company’s stock valued at $6,065,000 after purchasing an additional 48,750 shares during the period. Sei Investments Co. increased its stake in Supernus Pharmaceuticals by 24.4% in the 1st quarter. Sei Investments Co. now owns 330,580 shares of the specialty pharmaceutical company’s stock valued at $11,276,000 after buying an additional 64,752 shares during the period. Russell Investments Group Ltd. lifted its position in Supernus Pharmaceuticals by 205.2% in the 1st quarter. Russell Investments Group Ltd. now owns 97,988 shares of the specialty pharmaceutical company’s stock worth $3,342,000 after buying an additional 65,880 shares in the last quarter. Schroder Investment Management Group acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at $15,685,000. Finally, Vanguard Group Inc. grew its holdings in shares of Supernus Pharmaceuticals by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock valued at $179,854,000 after acquiring an additional 142,551 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts recently issued reports on SUPN shares. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Piper Sandler lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $41.00 to $36.00 in a report on Wednesday, September 11th.

Supernus Pharmaceuticals Stock Up 0.9 %

Shares of SUPN opened at $32.13 on Friday. The firm has a market cap of $1.77 billion, a price-to-earnings ratio of -110.79 and a beta of 0.88. The company’s fifty day moving average is $31.98 and its 200-day moving average is $30.43. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $35.44.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing the consensus estimate of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The business had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. During the same period in the previous year, the company earned ($0.02) earnings per share. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.